Gland Pharma Limited (GLAND.NS)
Company Info
| ISIN | INE068V01023 |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Highlights
| Market Cap | ₹332.73B |
|---|---|
| EPS (TTM) | ₹46.97 |
| PE Ratio | 43.00 |
| PEG Ratio | 9.08 |
| Total Revenue (TTM) | ₹44.56B |
| Gross Profit (TTM) | ₹22.34B |
| EBITDA (TTM) | ₹11.30B |
| Year Range | ₹1,250.25 - ₹2,194.00 |
| Target Price | ₹1,841.64 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of ₹10,000 in Gland Pharma Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Gland Pharma Limited had a return of 4.94% year-to-date (YTD) and 64.58% in the last 12 months.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 4.94% | 13.78% |
| 1 month | 10.77% | -0.38% |
| 6 months | 4.27% | 11.47% |
| 1 year | 64.58% | 18.82% |
| 5 years (annualized) | N/A | 12.44% |
| 10 years (annualized) | N/A | 10.64% |
Monthly Returns
The table below presents the monthly returns of GLAND.NS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 1.67% | -9.74% | 4.49% | -7.26% | 7.54% | -0.83% | 4.94% | ||||||
| 2023 | -17.48% | 1.31% | -3.78% | 7.14% | -32.00% | 14.98% | 23.06% | 33.18% | -3.81% | -7.71% | 14.79% | 8.44% | 22.07% |
| 2022 | -11.29% | -4.81% | 0.29% | -2.16% | -10.65% | -5.57% | -16.33% | 4.76% | -11.62% | -14.74% | -0.26% | -11.41% | -59.20% |
| 2021 | -9.55% | 13.48% | 3.19% | 12.24% | 13.38% | 8.58% | 14.78% | -0.93% | -4.47% | -0.53% | -3.10% | 7.79% | 65.17% |
| 2020 | 16.13% | 10.73% | 28.59% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current risk-adjusted rank of GLAND.NS is 89, placing it in the top 11% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Gland Pharma Limited (GLAND.NS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Gland Pharma Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Gland Pharma Limited was 79.30%, occurring on May 22, 2023. The portfolio has not yet recovered.
The current Gland Pharma Limited drawdown is 53.21%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -79.3% | Aug 13, 2021 | 438 | May 22, 2023 | — | — | — |
| -15.82% | Jan 6, 2021 | 18 | Feb 1, 2021 | 23 | Mar 4, 2021 | 41 |
| -11.2% | Mar 17, 2021 | 8 | Mar 26, 2021 | 13 | Apr 19, 2021 | 21 |
| -8.16% | May 20, 2021 | 23 | Jun 21, 2021 | 6 | Jun 29, 2021 | 29 |
| -7.42% | Dec 8, 2020 | 8 | Dec 17, 2020 | 4 | Dec 23, 2020 | 12 |
Volatility
Volatility Chart
The current Gland Pharma Limited volatility is 10.43%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
P/E Ratio
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Gland Pharma Limited.
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |